Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with moxonidine

B N Prichard1

  • 1Division of Clinical Pharmacology and Toxicology, University College London Medical School, Rayne Institute, United Kingdom.

Cardiovascular Drugs and Therapy
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term treatment of hypertension with labetalol.

British journal of clinical pharmacology·2015
Same author

Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

British journal of clinical pharmacology·2015
Same author

Proceedings of the Second Symposium on Labetalol, London, March 1979.

British journal of clinical pharmacology·2015
Same author

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Platelets·2010
Same author

Collagen-induced Platelet Activation In Vitro Increases Plasma Catecholamine Concentration.

Platelets·2010
Same author

Problems with Beta Adrenergic Blocking Drugs and other Antihypertensive Drugs.

Proceedings of the Royal Society of Medicine·2010

Moxonidine effectively lowers blood pressure by targeting I1-imidazoline receptors centrally. It shows comparable efficacy to other antihypertensives with a better side effect profile, particularly less tiredness and dry mouth than clonidine.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Internal Medicine

Background:

  • Moxonidine is a selective I1-imidazoline receptor agonist.
  • Stimulation of imidazoline receptors offers a novel central mechanism to reduce peripheral alpha-adrenergic tone.

Purpose of the Study:

  • To evaluate the antihypertensive efficacy and hemodynamic effects of moxonidine.
  • To compare moxonidine's safety and tolerability profile against other antihypertensive agents.

Main Methods:

  • Acute hemodynamic assessments and 6-month studies including left ventricular volume and hypertrophy.
  • Oral administration pharmacokinetic analysis and long-term open studies.
  • Comparative trials against clonidine, atenolol, ACE inhibitors, calcium antagonists, hydrochlorothiazide, and alpha-1 blockers.

Related Experiment Videos

Main Results:

  • Moxonidine acutely reduces blood pressure and systemic vascular resistance without affecting heart rate or cardiac output.
  • Left ventricular volumes decreased, and left ventricular hypertrophy regressed over 6 months.
  • Pharmacokinetics show rapid absorption (Tmax ~1 hour) and a short half-life (2.5 hours), with prolonged effect.
  • Open studies demonstrated significant systolic and diastolic blood pressure reductions.
  • Comparative trials showed similar blood pressure control to other drug classes, but moxonidine had a lower incidence of side effects, notably less tiredness and dry mouth compared to clonidine.

Conclusions:

  • Moxonidine is an effective antihypertensive agent with a favorable central mechanism of action.
  • It demonstrates good tolerability and a potentially superior side effect profile compared to some traditional antihypertensives.
  • Moxonidine offers a valuable therapeutic option for managing hypertension.